Value-based insurance design (VBID) might be good for the health care system, but insurers need to be clear on the advantages and disadvantages, argues health care economist Austin Frakt in the New York Times blog the Upshot. “It may be inevitable that health insurance comes with cost-sharing,” writes Frakt. “But there’s no reason it can’t be applied in ways that also help patients do the right thing, nudging them toward high-value care and decreasing incentives to pursue low-value care.”

Health plans deploying VBID offer better coverage for treatments that actually make a difference, and very little coverage for those that don’t. The idea isn’t new, but it’s starting to be applied more.

For instance, the ACA has VBID provisions that eliminates the cost-sharing for over 100 preventive services, such as cancer screenings and vaccinations. There are also programs in place by large employers and government entities that reduce cost-sharing for treatments aimed at chronic diseases such as diabetes.

This year, CMS began a five-year test of value-based design "that permits Medicare Advantage plans in seven states to reduce cost-sharing and enhance benefits for enrollees with designated chronic conditions,” Frakt writes. “Bipartisan legislation has been introduced in the House and Senate to expand the program nationwide.”

The question is: Does VBID actually work? Frakt cites several studies that showed some increase use in medication adherence for people with chronic conditions, but he calls them “modest.” He also talks about VBiD that focused on use of services other than pharmacy.

The programs seem to improve quality of life but don’t necessarily save money. For instance, Blue Cross and Blue Shield of North Carolina "reduced cost-sharing for hypertension, hyperlipidemia, diabetes and congestive heart failure medications for more than 700,000 policy holders. Their overall health care spending remained comparable to that of similar patients insured by other plans that did not use a value-based design.”

Source: New York Times

More Headlines

A couple of other steps may be waiting in the wings
The problem could undercut years of progress
New single-tablet regiment indicated for genotypes 1 to 6
Stop short of recommending public policy efforts
But they may be inching that way
Medicaid expansion looks safe for now, but nothing else is certain
Paratek is planning to submit an application in the first quarter of 2018
Neither replacing nor repealing the act have the votes they need